EP0858457A1 - Heterocycles a 5 chainons, medicaments contenant ces composes, utilisation et procede de production correspondants - Google Patents

Heterocycles a 5 chainons, medicaments contenant ces composes, utilisation et procede de production correspondants

Info

Publication number
EP0858457A1
EP0858457A1 EP96934603A EP96934603A EP0858457A1 EP 0858457 A1 EP0858457 A1 EP 0858457A1 EP 96934603 A EP96934603 A EP 96934603A EP 96934603 A EP96934603 A EP 96934603A EP 0858457 A1 EP0858457 A1 EP 0858457A1
Authority
EP
European Patent Office
Prior art keywords
group
carbon atoms
nitrogen atom
alkyl
piperidyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96934603A
Other languages
German (de)
English (en)
Inventor
Günter Linz
Frank Himmelsbach
Helmut Pieper
Volkhard Austel
Brian Guth
Johannes Weisenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1995139091 external-priority patent/DE19539091A1/de
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Publication of EP0858457A1 publication Critical patent/EP0858457A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • EP-A-O, 525, 629 and EP-A-O, 608, 858 already describe 5-membered heterocycles which have valuable pharmacological properties, preferably anti-aggregation effects.
  • the present invention thus relates to the above 5-membered heterocycles of the general formula I, which differ from the known 5-membered heterocycles by the radicals D and E, their tautomers, their stereoisomers including their mixtures and their salts, in particular their physiologically compatible salts with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably aggregation-inhibiting effects, medicaments containing these compounds and their use and processes for their preparation.
  • one of the radicals X ] _ to X5 is a group of the formulas A - B - N
  • A is a cycloalkyl group with 5 to 7 carbon atoms, optionally substituted by 1 to 4 alkyl groups, in which an unsubstituted methylene group is replaced by the R a -N ⁇ group, which is additionally substituted by a cyano, ammocarbonyl, carboxy, alkoxycarbonyl - Or phenylalkoxycarbonyl group or, if the substitution is not in the ⁇ -position to a nitrogen atom, may be substituted by a hydroxy, alkoxy, phenylalkoxy group, and in the
  • R a is a hydrogen atom, an alkyl group, a phenylalkyl group, an alkoxycarbonyl group with a total of 2 to 6 carbon atoms, a phenylalkoxycarbonyl group, an alkyleneoxycarbonyl group with a total of 4 to 6 carbon atoms, a cycloalkoxycarbonyl group with a total of 6 to 8 carbon atoms or one R] _- CO-0- (R2CH) -O-CO group in which
  • R ⁇ _ an alkyl group with 1 to 5 carbon atoms, a cycloalkyl group with 5 to 7 carbon atoms, a phenylalkyl group, an alkoxy group with 1 to 5 carbon atoms, a cycloalkoxy group with 5 to 7 carbon atoms or a phenyl group and
  • R2 represents a hydrogen atom, an alkyl group with 1 to 4 carbon atoms, a cycloalkyl group with 5 to 7 carbon atoms or a phenyl group,
  • B is a straight-chain or branched alkylene group with 1 to 8 carbon atoms, an alkenylene group with 2 or 3 carbon atoms, a -0 (CH 2 ) n ⁇ / - ( CH2 ) n 0_ ' -S (CH 2 ) n -, - ( CH 2 ) n S-, -CONR3-, -R3NCO-, -NR3 (CH2) n - or - (CH2) n NR3 group, in which
  • n is the number 1 or 2 and
  • R3 represents a hydrogen atom, a phenylalkyl group optionally substituted in the phenyl nucleus by a fluorine, chlorine or bromine atom or by an alkyl, hydroxy or alkoxy group, an alkyl or pyridylalkyl group and an oxygen, sulfur or nitrogen atom of the radical B not directly is connected to a nitrogen atom of the radical A or to a nitrogen atom of the 5-membered heterocycle,
  • a second of the radicals X] _ to X5 is a group of the formulas
  • D a -CO-, -CO-NR3-, -NR3-CO-, -S0 2 -NR 3 -, -NR 3 -S0 2 -, -W-CO-NR3-, -W; L-NR3-C0 -, -W2-S02NR3-, -W 1 -NR 3 S0 2 -, -C0-NR3-W! -, -NR3-C0-W! -, -S02NR3-W! -, -NR3SÜ2-W!
  • R3 and n are defined as mentioned above,
  • Wi is an alkylene group with 1 to 3 carbon atoms
  • W2 is an alkenylene group with 2 or 3 carbon atoms
  • W is an alkylene group having 1 to 3 carbon atoms or one
  • E is a phenylene group which can be mono- or disubstituted by fluorine, chlorine or bromine atoms, by alkyl, trifluoromethyl, R 3 O or R 3 ⁇ -CO-CH 2 ⁇ 0 groups, the substituents being identical or different can be and R 3 is defined as mentioned above,
  • a cycloalkylene group with 6 or 7 carbon atoms optionally substituted by an alkyl, phenylalkyl or phenyl group, in which one or two> CH units can each be replaced by a nitrogen atom, with additional a methylene group adjacent to a nitrogen atom can be replaced by a carbonyl group,
  • R3 and Wi are defined as mentioned above, R4 is an alkyl group with 1 to 5 carbon atoms, a phenylalkyl, phenyl or pyridyl group,
  • R5 is an alkyl group with 1 to 5 carbon atoms, a phenylalkyl, cycloalkyl or cycloalkylalkyl group and Y is an oxygen atom, a -CO-, sulfenyl-, sulfinyl-, sulfonyl-, -NR 3 -, -N (C0R4) -, -N (S0 2 R4) -, -CO-NR3- or -NR3-CO- group, where Y is linked to the radical E with the proviso that a heteroatom of the radical E is not attached to a nitrogen or sulfur atom of the above groups is bound,
  • R b is an alkyl group with 1 to 5 carbon atoms or a cycloalkyl group with 5 to 7 carbon atoms in the cycloalkyl part, it being possible for the above-mentioned groups in the alkyl and cycloalkyl part from position 2 in each case to be substituted by an R3O or R3R3N group , an alkenyl group with 3 to 5 carbon atoms, a phenylalkyl group, a cycloalkylalkyl group with 3 to 7 carbon atoms in the cycloalkyl part, which can be substituted in the alkyl part from position 2 by an R3O or R3R3N group, where R3 is in each case as defined above , a R ⁇ _-CO-0- (R2CH) group in which R] _ and R2 are defined as mentioned above, or a hydrogen atom, if the R ⁇ O-CO group is not directly bound to a nitrogen atom of the radical E,
  • the distance between the furthest nitrogen toffatom the group A and the group COOR ⁇ compounds is at least 11 Bin ⁇ as well as the above-mentioned AB and R j - j O-CO- FED-groups in 1,3-position to each other stand,
  • a third of the residues Xi to X5 is a sulfur atom, an HN ⁇ ,
  • R4 is as defined at the beginning and
  • R7 represents a hydrogen atom, an alkyl, phenylalkyl or phenyl group
  • a fourth of the radicals Xi to X 5 is an oxygen, sulfur or nitrogen atom or an R 7 C ⁇ group in which R 7 is defined as mentioned above,
  • radicals X ⁇ to X5 together form an o-phenylene group, but at least one of the radicals Xl to X5 in the aforementioned X 1 ⁇ X 5 ring must be a ring hetero atom,
  • the alkyl, alkylene or alkoxy parts mentioned above can each contain 1 to 3 carbon atoms and the cycloalkyl parts mentioned above can each contain 3 to 7 carbon atoms.
  • the general formula I mentioned above thus includes, for example, the correspondingly substituted furan, tetrahydrofuran, 2,3-dihydro-furan, 2,5-dihydro-furan, thiophene, 2,3-dihydro-thiophene , 2, 5-dihydro-thiophene, tetrahydrothiophene, pyrrole, indole, isoindole, 2,3-dihydro-indole, 2,3-dihydro-isoindole, imidazole, 4,5 -D ⁇ hydro- ⁇ m ⁇ dazol-, tetrahydro- imidazole-, benzimidazolm-, pyrazole-, 4, 5-d ⁇ hydro-pyrazole-, 2, 3-d
  • one of the residues Xi to X5 is a group of the formulas
  • A is a cycloalkyl group with 5 to 7 carbon atoms, optionally substituted by 1 to 4 alkyl groups, in which an unsubstituted methylene group is replaced by the R a -N ⁇ group, which is additionally replaced by a cyano, aminocarbonyl, carboxy or alkoxycarbonyl group or also if the substitution is not in the ⁇ -position to a nitrogen atom, can be substituted by a hydroxy or alkoxy group, and in which
  • R a is a hydrogen atom, an alkyl, phenylalkyl, alkoxycarbonyl or phenylalkoxycarbonyl group or an Rl-CO-0- (R2CH) -O-CO group in which Rl is an alkyl, cycloalkyl, phenyl, alkoxy or cycloalkoxy group each having 5 to 7 carbon atoms in the cycloalkyl part and
  • R2 represents a hydrogen atom or a methyl group
  • B is an alkylene group with 1 to 5 carbon atoms, an alkylene group with 2 or 3 carbon atoms, an -OCH2-, -CH 2 0-, -SCH 2 -, -CH 2 S-, -CONR3-, -R3NCO-, - NR 3 CH 2 or -CH2NR3 group in which
  • R3 represents a hydrogen atom, an alkyl, phenylalkyl or pyridylalkyl group and an oxygen, sulfur or nitrogen atom of the radical B is not directly connected to a nitrogen atom of the radical A or to a nitrogen atom of the 5-membered heterocycle,
  • a second of the radicals Xi to X5 is a group of the formulas
  • R 3 is defined as mentioned above,
  • Wi is an alkylene group with 1 to 3 carbon atoms
  • W2 is an alkenylene group with 2 or 3 carbon atoms
  • W is an alkylene group having 1 to 3 carbon atoms or one
  • E is a phenylene group which can be substituted by a fluorine, chlorine or bromine atom, by an alkyl, trifluoromethyl, R 3 O or R 3 ⁇ -CO-CH2 ⁇ 0 group, R 3 as before ⁇ standing is mentioned,
  • a pyridinylene, pyrimidinylene, pyrazinylene or pyridazinylene group each of which can be substituted in the carbon skeleton by an alkyl or alkoxy group
  • R3 and Wi are defined as mentioned above,
  • R4 is an alkyl group of 1 to 5 carbon atoms, one
  • R5 is an alkyl group of 1 to 5 carbon atoms or one
  • Y is an oxygen atom, a sulfenyl, -NR3-, -N (C0R4) - or
  • R b is an alkyl group with 1 to 5 carbon atoms or a cycloalkyl group with 5 to 7 carbon atoms in the cycloalkyl part, which in the alkyl and cycloalkyl part from position 2 onwards can each be substituted by an R3O or R3R3N group, an alkenyl group with 3 to 5 carbon atoms, a phenylalkyl group, a cycloalkylalkyl group with 3 to 7 carbon atoms in the cycloalkyl part, which can be substituted in the alkyl part from position 2 by an R3O or R3R3N group, where R3 is defined as mentioned above, a R1 CO-0- (R2CH) group in which R 1 and R 2 are defined as mentioned above, or also a hydrogen atom if the R b O-CO group is not bonded directly to a nitrogen atom of the radical E,
  • the distance between the most distant nitrogen atom of group A and the COOR ⁇ group is at least 11 binary fertilize and the above-mentioned AB and R b O-CO-FED groups are in the 1,3 position to one another,
  • a third of the radicals Xi to X5 is a sulfur atom, an HN ⁇ , R 4 N ⁇ , R 7 C ⁇ or (R 7 ) 2 C ⁇ group or an N atom, where
  • R4 is as defined at the beginning and
  • R 7 represents a hydrogen atom, an alkyl, phenylalkyl or phenyl group
  • a fourth of the radicals X j to X 5 ' is defined as mentioned above R a R 7 C ⁇ C group in which R 7 is an oxygen, sulfur or nitrogen atom ode,
  • a fifth of the radicals Xi to X5 is a nitrogen atom, an R 7 Cx or (R 7 > 2C ⁇ group, where R 7 is defined as mentioned above,
  • residues Xi to X5 together denote an o-phenylene group, but at least one of the residues Xi to X5 in the aforementioned X 1 ⁇ X 5 ring must be a ring hetero atom,
  • alkyl, alkylene or alkoxy parts mentioned above can each contain 1 to 3 carbon atoms,
  • particularly preferred compounds of the general formula I are those in which one of the residues Xi to X5 is a group of the formulas
  • A is a cycloalkyl group with 5 or 6 carbon atoms in which an unsubstituted methylene group in the 3- or 4-position is replaced by the R a -N ⁇ group in which
  • R a represents a hydrogen atom, a C ⁇ _2-alkyl, C ⁇ _4-alkoxycarbon- yl or benzyloxycarbonyl group,
  • a> CH unit in the 4-position can be replaced by a nitrogen atom
  • B is a bond, a C ⁇ _2-alkylene, -OCH2 or -CH2 ⁇ group,
  • a second of the radicals Xi to X5 is a group of the formulas
  • D is -CO-, -CO-NR3-, -NR3-CO-, -W-CO-NR3-, -CO-NR 3 -W1-, -NR3-CO-W1-, -CO-CH 2 -0 -, -O-Wi-, -W ⁇ ⁇ 0- or -W ⁇ ⁇ group or also a -W-CO group if the 5-membered Xi to X5 ⁇ ring is not an isoxazole ring, with the proviso that the vorste ⁇ groups are not bound via a carbonyl group to a nitrogen atom of the 5-membered heterocycle in which
  • R3 is a hydrogen atom, a C 4 alkyl, benzyl or pyridylmethyl group, Wi a C ⁇ _2 alkylene group and
  • W represent a C 2 alkylene or vinylene group
  • E is a 1,4-phenylene group, which can be substituted by a hydroxy, methoxy, carboxymethoxy or methoxycarbonylmethoxy group,
  • R3 and Wi are defined as mentioned above, R4 represents a methyl, ethyl or phenyl group and Y represents an oxygen atom, an -NR3 or -N (SO2R4) group, Y being linked to the radical E with the proviso that a nitrogen atom of the radical E is not bound to a nitrogen atom of the above groups and R3 and R4 are defined as mentioned above,
  • R b is a C 5 alkyl, cyclohexyl or benzyl group or also a hydrogen atom if the R b O-CO group is not bonded directly to a nitrogen atom of the radical E,
  • a third of the radicals Xi to X5 is an HN ⁇ , R41NK or R 7 C group or a nitrogen atom, where R4 is as defined at the beginning and
  • R 7 represents a hydrogen atom, a C 2-2 alkyl or phenyl group
  • a fourth of the radicals X] _ to X5 is an oxygen, sulfur or nitrogen atom or an R 7 C ⁇ group in which R 7 is defined as mentioned above,
  • a fifth of the radicals Xi to X 5 is a nitrogen atom or an R 7 C ⁇ ⁇
  • one of the residues Xi to X5 is a group of the formulas
  • A is a cyclohexyl group in which an unsubstituted methylene group in the 4-position is replaced by the R a -N ⁇ group in which
  • R a represents a hydrogen atom, a C ⁇ _4-alkoxycarbonyl or benzyloxycarbonyl group
  • B is a bond or a C 2 alkylene group
  • a second of the radicals Xi to X5 is a group of the formulas
  • R3 represents a hydrogen atom or a pyridylmethyl group
  • R b eme C ⁇ _4-alkyl or cyclohexyl group or a hydrogen atom if the R b O-CO group is not bonded directly to the nitrogen atom of the radical E,
  • R 7 represents a hydrogen atom or a methyl group
  • a fourth of the radicals Xi to X5 is a sulfur or nitrogen atom or an R 7 C " ⁇ group in which R 7 is defined as mentioned above,
  • a fifth of the radicals Xi to X5 is a nitrogen atom or an R 7 C ⁇ ⁇ '
  • R 7 is defined as mentioned above and at least one of the radicals Xi to X5 in the above-mentioned X ] _-X5 ring must be a ring heteroatom,
  • the new compounds are obtained by the following methods:
  • a ' has the meanings mentioned for A at the outset and additionally contains a protective radical which can be split off for an imino group
  • a second of the radicals Xi to X5 is a group of the formulas
  • RK, 1 has the meanings mentioned for R b and additionally represents a protective radical which can be removed from a hydroxyl group of a carboxyl group, but at least one of the radicals A 1 or RK, 'must contain or represent a removable protective radical,
  • R a em hydrogen atom and R b with the exception of the R ⁇ CO-0- (R 2 CH) group for the R b has the meanings mentioned at the outset, R a has the meanings mentioned for R a and R b em is a hydrogen atom or R a and R b are each a hydrogen atom.
  • Protective groups for an imino group can be, for example, acyl groups such as the formyl, acetyl, trifluoroacetyl or benzoyl group and carbonic acid ester residues such as the allyloxycarbonyl, ethoxycarbonyl, tert.butoxycarbonyl or benzyloxycarbonyl group by means of hydrolysis, Arylmethyl groups such as the benzyl group or arylmethyloxycarbonyl groups such as the benzyloxycarbonyl group by means of hydrogenolysis and
  • Carbonic acid ester residues with tertiary alcohols such as the tert-butyloxycarbonyl group can be split off by treatment with an acid or thermolysis and
  • Protective groups for a hydroxyl group of a carboxy group can be, for example, the functional derivatives of a carboxy group such as their unsubstituted or substituted amides, esters, thioesters, trimethylsilyl esters, orthoesters or immoesters by means of hydrolysis in a carboxyl group,
  • Esters with tertiary alcohols e.g. the tert. Butyl ester, by means of treatment with an acid or thermolysis in a carboxy group and
  • Esters with aralkanols e.g. the benzyl ester can be converted into a carboxyl group by means of hydrogeolysis.
  • the hydrolysis is expediently carried out either in the presence of an acid such as hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid or mixtures thereof or in the presence of a base such as lithium hydroxide, sodium hydroxide or potassium hydroxide in a suitable solvent such as Water, methanol, ethanol, isopropanol, ether, tetrahydrofuran, dioxane, methylene chloride or their mixtures at temperatures between -10 and 120 ° C, for example at temperatures between 0 ° C and the boiling point of the reaction mixture,
  • an acid such as hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid or mixtures thereof
  • a base such as lithium hydroxide, sodium hydroxide or potassium hydroxide
  • a suitable solvent such as Water, methanol, ethanol, isopropanol,
  • the hydrogenolysis expediently with hydrogen in the presence of a catalyst such as palladium / carbon in a solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, glacial acetic acid or trifluoroacetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100 ° C. preferably however at temperatures between 20 and 60 ° C, and at a hydrogen pressure of 1 to 7 bar, but preferably of 3 to 5 bar,
  • thermolysis expediently by heating, if appropriate in the presence of an acid such as trifluoroacetic acid and
  • the treatment with an acid is conveniently carried out in the presence of an acid such as trifluoroacetic acid, hydrogen bromide / glacial acetic acid or hydrogen chloride, optionally using a solvent such as methylene chloride, tetrahydrofuran, dioxane, methanol, ethanol, ether or mixtures thereof.
  • an acid such as trifluoroacetic acid, hydrogen bromide / glacial acetic acid or hydrogen chloride
  • a solvent such as methylene chloride, tetrahydrofuran, dioxane, methanol, ethanol, ether or mixtures thereof.
  • a corresponding compound of the general formula II is preferably m A 'contains a benzyloxycarbonyl group and R b ' is defined as mentioned above, using hydrogen bromide / glacial acetic acid at room temperature
  • R a em represents a hydrogen atom, a C 1-3 alkyl or phenyl C 3 alkyl group and R b em represents a hydrogen atom, preferably a corresponding compound of the general formula II in which A ' has the meanings mentioned for A at the outset and R 'is defined as mentioned above, using an acid such as hydrochloric acid or using a base such as sodium hydroxide or lithium hydroxide in a solvent such as methanol, tetrahydrofuran, water or mixtures thereof at temperatures between 0 ° C. and the boiling point of the solution used ⁇ medium, but preferably at temperatures between 0 and 40 ° C,
  • an acid such as hydrogen bromide / glacial acetic acid at temperatures between 0 ° C. and the boiling point of the solvent used, but preferably at temperatures between 0 and 40 ° C, converted into the desired compound.
  • RK. ' in a compound of formula II the tert. Butyl group and / or R a the tert. Butyloxycarbonyl ⁇ group these groups are particularly advantageous by treatment with an acid such as trifluoroacetic acid, formic acid, acetic acid, p-toluenesulfonic acid, sulfuric acid, hydrochloric acid, hydrogen bromide, phosphoric acid or polyphosphoric acid, optionally in a solvent such as methylene chloride, chloroform, Benzene, toluene, diethyl ether, tetrahydrofuran, dioxane, methanol, ethanol or their mixtures preferably at temperatures between -10 and 120 ° C, for example at temperatures between 0 and 60 ° C, or also thermally, if appropriate, in an inert solvent such as methylene chloride, Chloroform, benzene, toluene, tetrahydrofuran or dioxane
  • R a eme benzyl or benzyloxycarbonyl group and R b em benzyl group these protective groups are particularly preferred.
  • a hydrogenation catalyst such as palladium / carbon in a suitable solvent such as methanol, ethanol, ethanol / water, glacial acetic acid, ethyl acetate, dioxane or dimethylformamide, preferably at temperatures between 0 and 50 ° C., for example at room temperature, and one Split off hydrogen pressure from 1 to 5 bar.
  • hydrobromide is used as the starting compound in the hydrolysis of ester by means of hydrochloric acid
  • the corresponding hydrobromide is preferably obtained after evaporation of the hydrochloric acid and after recrystallization after evaporation of the hydrochloric acid.
  • R b represents -CO-FEDN ⁇ or group in which
  • Ui is a hydrogen atom of an imino group of the radical E, an HNR3 or HNR3 ⁇ W group or the last of the radicals Xi to X5 an HNR3 or HNR3-W1 group and
  • Ui mean a Z2-CO, Z2-SO2 / Z2-CO-W1 or Z2 ⁇ S02-W group, in which
  • Zi or Z2 denotes a nucleofugic leaving group such as a hydroxycarboxylic group is a halogen atom, eg a chlorine or bromine atom, an imidazolyl, 4-nitrophenyloxy or benzotriazol-1-oxy ⁇ .
  • a nucleofugic leaving group such as a hydroxycarboxylic group is a halogen atom, eg a chlorine or bromine atom, an imidazolyl, 4-nitrophenyloxy or benzotriazol-1-oxy ⁇ .
  • reaction is conveniently carried out in a solvent such as methylene chloride, dimethylformamide, dimethyl sulfoxide, benzene, toluene, chlorobenzene, tetrahydrofuran, dioxane or mixtures thereof, optionally in the presence of a dehydrating agent, e.g.
  • the sulfonic acid amides of the general formula I are obtained particularly advantageously by reacting a corresponding sulfonic acid halo, which is genids, preferably the chloride, with an appropriate amine.
  • Xl to X5 are as defined in the introduction, with the proviso that D in the second of the radicals Xi to X5 contains an alkenylene group with 2 or 3 carbon atoms.
  • the catalytic hydrogenation is preferably in a medium Amsterdams ⁇ as water, methanol, ethanol, tetrahydrofuran, dioxane or mixtures thereof at temperatures between 0 and 100 C C., preferably at temperatures between 20 ° C and the boiling temperature of the solvent used, carried out with hydrogen in the presence of a hydrogenation catalyst, for example in the presence of palladium / carbon, at a hydrogen pressure of 1 to 5 bar.
  • a hydrogenation catalyst for example in the presence of palladium / carbon
  • RK is an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 3 to 5 carbon atoms, a phenylalkyl group, a cycloalkyl or cycloalkylalkyl group each having 5 to 7 carbon atoms in the cycloalkyl part, represents a Rl-CO-0- (R2CH) group:
  • RK an alkyl group with 1 to 5 carbon atoms, an alkenyl group with 3 to 5 carbon atoms, a phenylalkyl group, a cycloalkyl or cycloalkylalkyl group each with 5 to 7 carbon atoms in the cycloalkyl part,
  • R c eme alkyl group with 1 to 5 carbon atoms, an alkenyl group with 3 to 5 carbon atoms, a phenylalkyl group, a cycloalkyl or cycloalkylalkyl group each with 5 to 7 carbon atoms in the cycloalkyl part, an Rl-CO-0- (R2CH) - Group in which
  • Rl and R2 as initially defined smd, and Z3 a leaving group such as a halogen atom, e.g. B. em chlorine or bromine.
  • a halogen atom e.g. B. em chlorine or bromine.
  • the reaction with an alcohol of the general formula VII is advantageously carried out in a solvent such as methylene chloride, benzene, toluene, chlorobenzene, ether, tetrahydrofuran, dioxane or mixtures thereof, but preferably in an alcohol of the general formula VII, if appropriate in the presence of a Acid such as hydrochloric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid or in the presence of a dehydrating agent
  • a solvent such as methylene chloride, benzene, toluene, chlorobenzene, ether, tetrahydrofuran, dioxane or mixtures thereof, but preferably in an alcohol of the general formula VII, if appropriate in the presence of a Acid such as hydrochloric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid or in the presence of a dehydrating agent
  • the reaction is advantageously carried out in a solvent such as methylene.
  • a solvent such as methylene.
  • Chloride, tetrahydrofuran, dioxane, dimethyl sulfoxide, dimethylformamide or acetone optionally in the presence of a reaction accelerator such as sodium or potassium iodide and preferably in the presence of a base such as sodium carbonate or potassium carbonate or in the presence of a tertiary organic base such as N -Ethyl-diisopropylamine or N-methyl-morpholine, which can also serve as a solvent, or, if appropriate, in the presence of silver carbonate or silver oxide at temperatures between -30 and 100 ° C, but preferably at temperatures between -10 and 80 ° C , carried out.
  • a reaction accelerator such as sodium or potassium iodide
  • a base such as sodium carbonate or potassium carbonate
  • a tertiary organic base such as N -Ethyl-diiso
  • Z4 and Z5 which may be the same or different, halogen atoms, amino groups optionally substituted by R7, where in R7 as defined at the outset, represent hydroxyl, alkoxy, mercapto or alkyl mercapto groups.
  • reaction is conveniently carried out in a solvent such as tetrahydrofuran, dioxane, 1,2-dichlorobenzene or pyridine at temperatures up to the boiling point of the solvent used, e.g. at temperatures between 20 and 180 ° C.
  • a solvent such as tetrahydrofuran, dioxane, 1,2-dichlorobenzene or pyridine
  • a tautomeric compound of the general formula VI Z4 and Z5 each represents a hydroxyl group
  • the reaction is preferably carried out in the presence of a dehydrating agent such as thionyl chloride for the preparation of a 1, 3, 4-olderxadiazole derivative,
  • a 1, 3, 4-thiadiazole derivative the reaction preferably in the presence of a sulfur-introducing reagent such as, for example, 2, 4-bis (4-methoxyphenyl) -1, 3-dithia-2, 4-diphosphetane-2, 4-disulfide and
  • the reaction is preferably carried out in the presence of a halogen-introducing agent such as phosphorus trichloride and in the presence of aniline.
  • a halogen-introducing agent such as phosphorus trichloride
  • any reactive groups present such as carboxy, amino or imino groups, can be protected during the reaction by customary protective groups, which are split off again after the reaction.
  • the trimethylsilyl, methyl, ethyl, tert-butyl, benzyl or tetrahydropyranyl group comes as a protective radical for a carboxyl group as a protective radical for an amino or imino group, the formyl, acetyl, trifluoroacetyl, allyloxycarbonyl, ethoxycarbonyl, tert.butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2, 4-dimethoxybenzyl group and for the amino group ⁇ additionally the phthalyl group into consideration.
  • the subsequent subsequent splitting off of a protective residue used takes place, for example, hydrolytically in an aqueous solvent, e.g. in water, isopropanol / water, acetic acid / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid or in the presence of an alkali base such as sodium hydroxide or lithium hydroxide or by means of ether cleavage, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120 ° C, preferably at temperatures between 10 and 100 ° C.
  • an aqueous solvent e.g. in water, isopropanol / water, acetic acid / water, tetrahydrofuran / water or dioxane / water
  • an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid
  • a benzyl, methoxybenzyl or benzyloxycarbonyl radical is split off, for example by hydrogenolysis, e.g. with hydrogen in the presence of a catalyst such as palladium / carbon in a solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100 ° C, but preferably at temperatures between 20 and 60 ° C, and at a hydrogen pressure of 1 to 7 bar, but preferably from 3 to 5 bar.
  • a 2,4-dimethoxybenzyl radical is preferably cleaved in trifluoroacetic acid in the presence of anisole.
  • a tert-butyl or tert-butyloxycarbonyl radical is preferably cleaved off by treatment with an acid such as trifluoroacetic acid or hydrochloric acid or by treatment with iodotrimethylsilane, optionally using a solvent such as methylene chloride, dioxane, methanol or ether.
  • a trifluoroacetyl radical is preferably cleaved off by treatment with an acid such as hydrochloric acid, if appropriate in the presence of a solvent such as acetic acid at structures between 50 and 120 ° C or by treatment with sodium hydroxide solution or aqueous lithium hydroxide solution, optionally in the presence of a solvent such as tetrahydrofuran or methanol at temperatures between 0 and 50 ° C.
  • an acid such as hydrochloric acid
  • a solvent such as acetic acid at structures between 50 and 120 ° C or by treatment with sodium hydroxide solution or aqueous lithium hydroxide solution, optionally in the presence of a solvent such as tetrahydrofuran or methanol at temperatures between 0 and 50 ° C.
  • An allyloxycarbonyl radical is cleaved off by treatment with a catalytic amount of tetrakis (triphenylphosphine) palladium (O), preferably in a solvent such as tetrahydrofuran and preferably in the presence of an allyl group acceptor such as morpholine or 1,3-dmedon at temperatures between 0 and 100 ° C, preferably at room temperature and under inert gas, or by treatment with a catalytic amount of tris (triphenylphosphine) rhodium (I) chloride in a solvent such as aqueous ethanol and optionally in the presence of a base such as 1.4 -D ⁇ azab ⁇ cyclo [2.2.2] octane at temperatures between 20 and 70 ° C.
  • a catalytic amount of tetrakis (triphenylphosphine) palladium (O) preferably in a solvent such as tetrahydrofuran and preferably in the
  • a phthalyl radical is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene / water or dioxane at temperatures between 20 and 50 ° C.
  • the compounds of general formula I obtained can be separated into their enantiomers and / or diastereomers.
  • cis / trans mixtures can be separated into their ice and trans isomers, and compounds with at least one optically active carbon atom can be separated into their enantiomers.
  • the cis / trans mixtures obtained can be chromatographed in their ice and trans isomers, the compounds of general formula I obtained which occur in racemates, by methods known per se (see Allmger NL and Eliel EL m "Topics m Stereochemistry", Vol. 6, Wiley Interscience, 1971) in their optical antipodes and compounds of general formula I with at least 2 Separate reogenic centers into their diastereomers on the basis of their physico-chemical differences according to methods known per se, for example by chromatography and / or fractional crystallization, which, if they occur in racemic form, subsequently as mentioned above in the enantiomers can be separated.
  • the separation of enantiomers is preferably carried out by column separation on chiral phases or by recrystallization from an optically active solvent or by reaction with a salt or derivative, such as e.g. Optically active substance which forms esters or amides, in particular acids and their activated derivatives or alcohols, and separation of the diastereomeric salt mixture or derivative obtained in this way, e.g. due to various solubilities, the free antipodes being able to be released from the pure diastereomeric salts or derivatives by the action of suitable agents.
  • a salt or derivative such as e.g. Optically active substance which forms esters or amides, in particular acids and their activated derivatives or alcohols
  • Suitable optically active alcohols are, for example, (+) - or (-) menthol, and optically active acyl radicals in amides are, for example, (+) - or (-) - menthyloxycarbonyl.
  • the compounds of the formula I obtained can be converted into their salts, in particular for pharmaceutical use into their physiologically tolerable salts with inorganic or organic acids.
  • Suitable acids are, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.
  • the new compounds of the formula I obtained in this way contain a carboxyl group, they can, if desired, be subsequently converted into their salts with inorganic or organic convert ganic bases, in particular for pharmaceutical use, into their physiologically tolerable salts.
  • Suitable bases are, for example, sodium hydroxide, potassium hydroxide, arginine, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.
  • the new 5-membered heterocycles of the general formula I and their salts in particular their physiologically tolerable salts with inorganic or organic acids or bases, have valuable pharmacological properties, in addition to anti-inflammatory and bone-degrading Effect in particular antithrombotic, antiaggregatory and tumor or metastasis-inhibiting effects.
  • donor blood is drawn from an anti-cubital vein and anticoagulated with trisodium citrate (final concentration 13 mM).
  • the blood is centrifuged at 170 xg for 10 minutes and that protruding platelet-rich plasma (PRP) removed.
  • PRP platelet-rich plasma
  • the remaining blood is again centrifuged sharply to obtain plasma.
  • the PRP is diluted 1:10 with autologous plasma. 750 ml are incubated with 50 ml of physiological saline, 100 ml of test substance solution, 50 ml of 14 C sucrose (3,700 Bq) and 50 ml of 3 H-BIBU 52 (final concentration: 5 nM) at room temperature for 20 minutes.
  • 5 ml BIBU 52 (final concentration: 30 mM) is used instead of the test substance.
  • the samples are centrifuged at 10,000 xg for 20 seconds and the supernatant is removed. 100 ml of this are measured to determine the free ligand.
  • the pellet is dissolved in 500 ml of 0.2N NaOH, 450 ml are mixed with 2 ml of scintillator and 25 ml of 5N HCl and measured. The residual plasma remaining in the pellet is determined from the 14 C content, the bound ligand from the 3 H measurement. After subtracting the non-specific binding, the pellet activity is plotted against the concentration of the test substance and the concentration for 50% inhibition of binding is determined.
  • Platelet aggregation is measured using the method of Born and Cross (J. Physiol. 1/70, 397 (1964)) in platelet-rich plasma from healthy subjects. In order to inhibit coagulation, sodium citrate 3.14% in a volume ratio of 1:10 is added to the blood.
  • the course of the decrease in the optical density of the plate suspension is measured and recorded photometrically after the addition of the aggregation-triggering substance.
  • the rate of aggregation is inferred from the angle of inclination of the density curve.
  • the point of the curve at which the greatest light transmission Reliability is used to calculate the "optical density".
  • the amount of collagen is chosen to be as small as possible, but in such a way that an irreversible reaction curve results.
  • the commercial collagen from Hormonchemie, Kunststoff, is used.
  • the plasma is incubated with the substance at 37 ° C. for 10 minutes.
  • An EC5 0 which relates to a 50% change in the "optical density" in the sense of an inhibition of aggregation, is determined graphically from the measurement numbers obtained.
  • the new 5-membered heterocycles of the general formula I and their physiologically tolerable salts are suitable for combating or preventing diseases which have smaller or larger cell aggregates or cell-matrix interactions play a role, for example in combating or preventing venous and arterial thrombosis, cerebrovascular diseases, pulmonary embolism, myocardial infarction, arteriosclerosis, osteoporosis and meta staging of tumors and the therapy of genetically determined or acquired disorders in the interactions of cells with one another or with solid structures.
  • These are also suitable for accompanying therapy in the case of thrombolysis with fibrinolytics or vascular interventions such as transluminal angioplasty or also in the therapy of shock conditions, psoriasis, diabetes and inflammation.
  • the dose is between 0.1 mg and 30 mg / kg body weight, preferably 1 mg to 15 mg / kg body weight, with up to 4 doses per day.
  • the compounds of the formula I prepared according to the invention optionally in combination with other active substances such as thromboxane receptor antagonists and thromboxane synthesis inhibitors or their i combinations, serotonin antagonists, ⁇ -receptor antagonists,
  • Alkyl nitrates such as glycerol trinitrate, phosphodiesterase inhibitors, prostacyclin and their analogs, fibrinolytics such as tPA, prourokinase, urokinase, streptokinase, or anticoagulants such as heparin, dermatan sulfate, activated protein C, vitamin K antagonists or other hirudin inhibitors, hirudin, inhibitors Akti ⁇ fourth coagulation factors, together with one or more inert conventional carriers and / or diluents, for example with corn starch, milk sugar, cane sugar, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerol, what ⁇ ser / sorbitol, water / polyethylene glycol, propylene glycol, stearyl alcohol, carboxymethyl cellulose or fatty substances such as hard fat
  • IM lithium hydroxide solution is used instead of IM sodium hydroxide solution.
  • the hydrolysis is carried out with lithium hydroxide in tetrahydrofuran / water (4: 5).
  • the red product is mixed with methylene chloride / methanol / conc.
  • Ammonia (4: 1: 0.2) chromatographed over silica gel.
  • IM lithium hydroxide solution is used instead of IM sodium hydroxide solution.
  • Rf value: 0.16 (silica gel; methylene chloride / methanol 10: 1)
  • Ethyl 2-chloro-3-hydroxyacrylic acid is used.
  • the reaction solution is heated to reflux for 2.5 days. After 2 days, a further 0.5 equivalent of 2-chloro-3-hydroxyacrylic acid ethyl ester is added.
  • methanesulfonic acid [2- [1- (tert.butyloxycarbonyl) -4-piperidyl] ethyl] ester (prepared by reduction of [1- (tert.butyloxycarbonyl) -4-piperidyl] acetic acid methyl ester with lithium borohydride in tetrahydrofuran and subsequent esterification with methanesulfonyl chloride Ver ⁇ in methylene chloride in Ge genwart of triethylamine, melting point: 85.5-87.5 c setsteil ⁇ C). The mixture is stirred for 4 days at room temperature.
  • Example XXIV Manufactured analogously to Example VIII. The mixture is stirred for 4 hours at room temperature. After neutralization, the organic solvent is evaporated off and the solution
  • a suspension of 9.0 g of (4-hydroxyphenyloxy) acetic acid benzyl ester [prepared by esterifying (4-hydroxyphenyloxy) acetic acid with benzyl alcohol analogously to Example 8; Melting point: 69-71 ° C.] and 9.7 g of potassium carbonate in 100 ml of dimethylformamide are stirred at room temperature for 30 minutes.
  • 6.7 g of ethyl bromoacetate are added dropwise and the mixture is stirred at room temperature for 16 hours and at 70 ° C. for 1 hour.
  • the reaction solution is evaporated and the residue is partitioned between ethyl acetate / water.
  • the organic phase is washed with saturated sodium chloride solution, dried and evaporated.
  • the starting material is 5 - [[[1- (tert-butyloxycarbonyl-methyl) -4-piperidyl] methyl] aminocarbonyl] -4-methyl-2- [1- (phenylmethyloxycarbonyl) -4-piperidyl] -1, 3-thiazole used.
  • Mass spectrum: M + 380
  • Example 2 The compound of Example 2 (4) is used as starting material.
  • Example 2 The compound of Example 2 (5) is used as starting material.
  • Example 2 (6) The compound of Example 2 (6) is used as starting material.
  • the hydrolysis is carried out with lithium hydroxide in tetrahydrofuran / water (5: 4). After 5 hours, acidify with IN hydrochloric acid.
  • the hydrolysis is carried out with lithium hydroxide in tetrahydrofuran / water (5: 4).
  • the crude product is mixed with methylene chloride / methanol / conc.
  • Ammonia (2: 1: 0.2) chromatographed over silica gel.
  • Active ingredient and mannitol are dissolved in water. After filling, freeze-drying. The dissolution for the ready-to-use solution takes place with water for injection purposes.
  • Active ingredient and mannitol are dissolved in water. After filling, freeze-drying.
  • (1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with intensive mixing.
  • This powder mixture is filled into size 3 hard gelatin capsules on a capsule filling machine.
  • (1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with intensive mixing.
  • This powder mixture is filled in a size 0 hard gelatin capsule on a capsule filling machine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

L'invention concerne des hétérocycles à 5 chaînons de la formule générale (I) où X1 à X5 sont définis dans la revendication 1, leurs tautomères, leurs stéréoisomères, y compris leur mélange, et leurs sels, notamment leurs sels contenant des acides ou bases physiologiquement tolérables, lesquels présentent de précieuses propriétés pharmacologiques, de préférence des effets inhibiteurs d'aggrégation. L'invention concerne également les médicaments contenant ces composés, leur utilisation et le procédé de production correspondant.
EP96934603A 1995-10-20 1996-10-10 Heterocycles a 5 chainons, medicaments contenant ces composes, utilisation et procede de production correspondants Withdrawn EP0858457A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19539091 1995-10-20
DE1995139091 DE19539091A1 (de) 1995-10-20 1995-10-20 5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung
DE1995148798 DE19548798A1 (de) 1995-10-20 1995-12-27 5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
DE19548798 1995-12-27
PCT/EP1996/004390 WO1997015567A1 (fr) 1995-10-20 1996-10-10 Heterocycles a 5 chainons, medicaments contenant ces composes, utilisation et procede de production correspondants

Publications (1)

Publication Number Publication Date
EP0858457A1 true EP0858457A1 (fr) 1998-08-19

Family

ID=26019640

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96934603A Withdrawn EP0858457A1 (fr) 1995-10-20 1996-10-10 Heterocycles a 5 chainons, medicaments contenant ces composes, utilisation et procede de production correspondants

Country Status (5)

Country Link
US (1) US5817677A (fr)
EP (1) EP0858457A1 (fr)
JP (1) JPH11513382A (fr)
CA (1) CA2229617A1 (fr)
WO (1) WO1997015567A1 (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
CA2352957A1 (fr) * 1999-09-29 2001-04-05 Ortho-Mcneil Pharmaceutical, Inc. Isonipecotamides destinees au traitement de maladies provoquees par l'integrine
CA2389681C (fr) 1999-11-26 2010-11-02 Shionogi & Co., Ltd. Antagonistes npy y5
GB0005477D0 (en) * 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
UA82048C2 (uk) * 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
DE60208186T2 (de) * 2001-04-09 2006-08-24 Ortho-Mcneil Pharmaceutical Research Inc. Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrin-vermittelten erkrankungen
CN101104598B (zh) 2002-03-12 2011-06-15 盐野义制药株式会社 反式-4-氨基-1-环己烷羧酸衍生物的制备方法
GB0230162D0 (en) * 2002-12-24 2003-02-05 Metris Therapeutics Ltd Compounds useful in inhibiting angiogenesis
FR2856685B1 (fr) * 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
FR2865733B1 (fr) * 2004-02-04 2007-10-12 Merck Sante Sas Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine
US7541472B2 (en) * 2004-05-24 2009-06-02 Cropsolution, Inc. 3-Aryl-3-hydroxy-2-methylenepropionic acid esters as fungicides
JP2008509088A (ja) * 2004-09-02 2008-03-27 ファイザー株式会社 ベンズイミダゾロンカルボン酸誘導体
CA2580762A1 (fr) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
EP1637529A1 (fr) 2004-09-20 2006-03-22 4Sc Ag Nouveaux analogues de piperidin-4-yl-thiazole-carboxamide en tant qu'inhibiteurs de proliferation de lymphocytes T er leurs utilisations
WO2006032322A1 (fr) * 2004-09-20 2006-03-30 4Sc Ag NOUVEAUX INHIBITEURS HÉTÉROCYCLIQUES DU NF-κB
US7601745B2 (en) * 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
EP1838311A1 (fr) * 2004-12-24 2007-10-03 Prosidion Limited Agonistes du récepteur couplé aux protéines g (gpr116) et leur emploi dans le traitement de l'obésité et du diabète
EP1910290A2 (fr) * 2005-06-30 2008-04-16 Prosidion Limited Agonistes de gpcr
TW200738701A (en) 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2114955B1 (fr) 2006-12-29 2013-02-13 Rigel Pharmaceuticals, Inc. Triazoles substitués par aryle bicyclique ponté et hétéroaryle bicyclique ponté utilisés comme inhibiteurs d'axl
PE20081849A1 (es) * 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
CL2008000018A1 (es) * 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
US20100048632A1 (en) * 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine GPCR Agonists
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
DE102007047735A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Thiazolderivate
BRPI0909469A2 (pt) * 2008-03-31 2015-12-29 Metabolex Inc compostos de oximetileno de arila e usos dos mesmos
US8377968B2 (en) * 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
US8410127B2 (en) * 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
CN109674753A (zh) 2010-06-23 2019-04-26 希玛贝治疗股份有限公司 固态分散体
RU2576316C2 (ru) 2010-11-03 2016-02-27 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидная композиция, способ контроля вредителей, способ контроля эндопаразитов, эктопаразитов или обоих и способ усиления жизнестойкости растений
EP2723718A1 (fr) 2011-06-24 2014-04-30 Amgen Inc. Antagonistes de trpm8 et leur utilisation dans le cadre thérapeutique
US8710043B2 (en) 2011-06-24 2014-04-29 Amgen Inc. TRPM8 antagonists and their use in treatments
SMT201800171T1 (it) 2011-07-29 2018-07-17 Karyopharm Therapeutics Inc Modulatori di trasporto nucleare contenenti idrazide e loro usi
US9428490B2 (en) * 2011-07-29 2016-08-30 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
JP6027128B2 (ja) 2011-10-26 2016-11-16 ダウ アグロサイエンシィズ エルエルシー 有害生物防除組成物およびそれに関連した方法
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
BR122014028247A2 (pt) 2012-04-27 2019-05-07 Dow Agrosciences Llc composições pesticidas, processo para controlar praga, uso de uma molécula, processo para aumentar a saúde, rendimento, vigor, qualidade ou tolerância de uma planta e processos para produção de compostos
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
CA2872190C (fr) 2012-05-09 2024-06-25 Karyopharm Therapeutics, Inc. Modulateurs du transport nucleaire et leurs utilisations
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
AU2013355054B2 (en) 2012-12-07 2017-08-24 Chemocentryx, Inc. Diazole lactams
US9169248B2 (en) 2012-12-21 2015-10-27 Chemocentryx, Inc. Diazole amides
US10202366B2 (en) 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
DK3492455T3 (da) 2013-06-21 2023-08-14 Karyopharm Therapeutics Inc 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer
CA2925952A1 (fr) 2013-10-17 2015-04-23 Dow Agrosciences Llc Procedes de preparation de composes pesticides
US9029554B1 (en) 2013-10-17 2015-05-12 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CA2926095A1 (fr) 2013-10-17 2015-04-23 Dow Agrosciences Llc Procedes de preparation de composes pesticides
EP3057429A4 (fr) 2013-10-17 2017-08-09 Dow AgroSciences LLC Procédés de préparation de de composés pesticides
CA2925953C (fr) 2013-10-17 2021-11-02 Dow Agrosciences Llc Procedes de preparation de composes pesticides
MX2016004941A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Proceso para la preparacion de compuestos plaguicidas.
JP2016539092A (ja) 2013-10-17 2016-12-15 ダウ アグロサイエンシィズ エルエルシー 有害生物防除性化合物の製造方法
US9788545B2 (en) 2013-10-22 2017-10-17 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
KR20160074628A (ko) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 상승작용적 살충 조성물 및 관련 방법
MX2016005305A (es) 2013-10-22 2017-03-01 Dow Agrosciences Llc Composiciones pesticidas sinergicas y metodos relacionados.
TW201517797A (zh) 2013-10-22 2015-05-16 Dow Agrosciences Llc 協同性殺蟲組成物及相關方法（十一）
US9801383B2 (en) 2013-10-22 2017-10-31 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
JP2016534073A (ja) 2013-10-22 2016-11-04 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
US9295260B2 (en) 2013-10-22 2016-03-29 Dow Agrosciences Llc Pesticidal compositions and related methods
NZ719776A (en) 2013-10-22 2017-06-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
US9282740B2 (en) 2013-10-22 2016-03-15 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
AR098101A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas y métodos relacionados
NZ719952A (en) 2013-10-22 2017-05-26 Dow Agrosciences Llc Pesticidal compositions and related methods
AU2014340424B2 (en) 2013-10-22 2017-06-29 Dow Agrosciences Llc Pesticidal compositions and related methods
RU2656894C2 (ru) 2013-10-22 2018-06-07 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидные композиции и соответствующие способы
AR098099A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas sinérgicas y los métodos relacionados
AR098100A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas y los métodos relacionados
EP3060044A4 (fr) 2013-10-22 2017-04-05 Dow AgroSciences LLC Compositions pesticides synergiques et procédés associés
JP2016535026A (ja) 2013-10-22 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
US9249122B1 (en) 2014-07-31 2016-02-02 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
JP2017523168A (ja) 2014-07-31 2017-08-17 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの製造方法
BR112017000293A2 (pt) 2014-07-31 2017-10-31 Dow Agrosciences Llc processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina
CN111484483B (zh) 2014-08-15 2023-05-26 卡尔约药物治疗公司 赛灵克斯的多晶型物
JP2017525703A (ja) 2014-08-19 2017-09-07 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの調製方法
AR098113A1 (es) 2014-09-12 2016-05-04 Dow Agrosciences Llc Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina
SG11201710694YA (en) 2015-06-22 2018-01-30 Sumitomo Dainippon Pharma Co Ltd Bicyclic heterocyclic amide derivative
CN107922386B (zh) 2015-06-22 2021-04-02 大日本住友制药株式会社 1,4-二取代的咪唑衍生物
WO2017117535A1 (fr) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Modulateurs de transport nucléaire et leurs utilisations
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10898469B2 (en) 2016-02-26 2021-01-26 Sumitomo Dainippon Pharma Co., Ltd. Imidazolylamide derivative
CN109310677A (zh) 2016-04-07 2019-02-05 凯莫森特里克斯股份有限公司 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
CN110325036B (zh) 2016-12-29 2021-10-26 美国陶氏益农公司 用于制备杀虫化合物的方法
JP2020503336A (ja) 2016-12-29 2020-01-30 ダウ アグロサイエンシィズ エルエルシー 殺有害生物化合物の調製方法
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
WO2020113094A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4302051A1 (de) * 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
BR9408137A (pt) * 1993-11-24 1997-08-12 Du Pont Merck Pharma Composto éster de prodroga método de tratamento composição farmacêutica e método de inibição
AU4432496A (en) * 1994-12-23 1996-07-19 Dr. Karl Thomae Gmbh Piperazine derivatives, medicaments containing the same, their use and process for preparing the same
US5668159A (en) * 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9715567A1 *

Also Published As

Publication number Publication date
CA2229617A1 (fr) 1997-05-01
WO1997015567A1 (fr) 1997-05-01
US5817677A (en) 1998-10-06
MX9802988A (es) 1998-09-30
JPH11513382A (ja) 1999-11-16

Similar Documents

Publication Publication Date Title
EP0858457A1 (fr) Heterocycles a 5 chainons, medicaments contenant ces composes, utilisation et procede de production correspondants
DE4302051A1 (de) 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0528369B1 (fr) Dérivés à fonction imine cyclique, compositions pharmaceutiques les contenant et procédé pour leur préparation
DE602004012969T2 (de) Phenylacetamide und ihre verwendung als glukokinase-modulatoren
DE69919212T2 (de) Aromatische amiden
DE4234295A1 (de) Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1587795A1 (fr) Derives de n- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyle) -1-piperidine-carboxamide et composes apparentes utilises comme antagonistes de cgrp et destines au traitement des maux de tete
DE4134467A1 (de) Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0574808A1 (fr) Dérivés des amidines-biphenyles, un procédé pour leurs préparation et des médicaments les contenant
EP0567966A1 (fr) Composés imino cycliques, médicaments les contenant et procédés pour leur préparation
DE19851421A1 (de) Neue Pyrimidine, deren Herstellung und Verwendung
DE4326344A1 (de) Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2003024451A1 (fr) Derives de 2-(2-phenylethyl)-benzimidazol-5-carboxamide et leur utilisation comme inhibiteurs de la tryptase
DE19548798A1 (de) 5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
WO2001047896A1 (fr) Benzimidazoles, leur production et leur utilisation comme antithrombotiques
DE10109867A1 (de) Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE19515500A1 (de) Substituierte Phenylamidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4424975A1 (de) 2-Piperidinone, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1997048702A1 (fr) Derives de benzazepine, medicaments contenant ces composes et procede permettant de les preparer
DE19607436A1 (de) Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1995024405A1 (fr) Imidazolidin-2-ones, medicaments contenant ces composes et leur procede de preparation
CH652123A5 (de) Azaspiroalkandione, verfahren zu ihrer herstellung und pharmazeutische mittel, die diese verbindungen enthalten.
DE19533224A1 (de) Piperazinderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2001014355A1 (fr) Derives de piperazine substitues, leur fabrication et leur utilisation comme medicaments
DE4309213A1 (de) Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980520

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19991228

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000509